The ADEPT-4 study is evaluating the safety and efficacy of the investigational medicine, KarXT, for the treatment of psychosis associated with Alzheimer’s disease. The total study duration for an individual is approximately 20 weeks. There is also an option to participate in a continuation study for the next year.
To be eligible, a patient must:
- Be between the ages of 55 and 90 years old
- Have been diagnosed with mild to severe Alzheimer’s disease with moderate to severe psychosis (hallucinations and/or delusions)
- Have a caregiver that will be able to attend all visits, oversee medication and treatment, and participate in written study assessments
If you would like to receive additional information on the ADEPT-4 study or have any qualified patients to refer, please email PI Dr. Neha Jain (njain@uchc.edu) or lead RA Marcia Lawlor (lawlor@uchc.edu).
For more information, contact: Neha Jain at njain@uchc.edu